{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:35:55Z","timestamp":1792697755198,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies have shown that losartan reduces serum uric acid in adults, unlike angiotensin-converting enzyme inhibitors. A previous study demonstrated that losartan and enalapril had comparable effects on proteinuria in children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a post hoc analysis of results from a prospective trial in which the proteinuria-reducing effects of losartan and enalapril were compared. We have now evaluated (a) the effects of these medications on SUA in 248 children with proteinuria and (b) the correlation between changes in SUA and eGFR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SUA levels after 36 months were found to be increased when compared to baseline in both losartan and enalapril groups. The mean change in SUA from baseline was significantly different at 12 months between 23 hypertensive patients randomised to losartan (3.69% decrease [95% CI 11.31%, 3.93%]) and 24 randomised to enalapril (12.57% increase [95% CI 3.72%, 21.41%]), <jats:italic>p<\/jats:italic> = 0.007. This significant difference remained after 24, 30 and 36 months but was observed in the entire group of 248 patients only at 12 months. There was a statistically significant negative correlation between changes in SUA and changes in eGFR at each time point over 36 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Losartan may have long-term beneficial effects on SUA and eGFR in children with proteinuria.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00467-021-05045-4","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T04:04:25Z","timestamp":1618977865000},"page":"3211-3219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4364-9315","authenticated-orcid":false,"given":"Charlotte E.","family":"Bryant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azita","family":"Rajai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"5045_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1681\/ASN.2005121331","volume":"17","author":"DI Feig","year":"2006","unstructured":"Feig DI, Mazzali M, Kang DH, Nakagawa T, Price K, Kannelis J, Johnson RJ (2006) Serum uric acid: a risk factor and a target for treatment. J Am Soc Nephrol 17:69\u201373","journal-title":"J Am Soc Nephrol"},{"key":"5045_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","volume":"359","author":"DI Feig","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359:1811\u20131821","journal-title":"N Engl J Med"},{"key":"5045_CR3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","volume":"44","author":"K Iseki","year":"2004","unstructured":"Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S (2004) Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 44:642\u2013650","journal-title":"Am J Kidney Dis"},{"key":"5045_CR4","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1681\/ASN.2008010080","volume":"19","author":"RP Obermayr","year":"2008","unstructured":"Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Obermauer R, Klauser-Braun R (2008) Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 19:2407\u20132413","journal-title":"J Am Soc Nephrol"},{"key":"5045_CR5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","volume":"19","author":"DE Weiner","year":"2008","unstructured":"Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS (2008) Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19:1204\u20131211","journal-title":"J Am Soc Nephrol"},{"key":"5045_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","volume":"56","author":"G Bellomo","year":"2010","unstructured":"Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M (2010) Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 56:264\u2013272","journal-title":"Am J Kidney Dis"},{"key":"5045_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000326848","volume":"33","author":"H Sonoda","year":"2011","unstructured":"Sonoda H, Takase H, Dohi Y, Kimura G (2011) Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 33:352\u2013357","journal-title":"Am J Nephrol"},{"key":"5045_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/nep.12679","volume":"22","author":"Y-P Hsieh","year":"2017","unstructured":"Hsieh Y-P, Chang C-C, Yang Y, Wen Y-K, Chiu P-F, Lin C-C (2017) The role of uric acid in chronic kidney disease patients. Nephrology 22:441\u2013448 https:\/\/doi.org\/1111\/nep.12679","journal-title":"Nephrology"},{"key":"5045_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/ndt\/gfx297","volume":"33","author":"C-W Tsai","year":"2018","unstructured":"Tsai C-W, Chiu H-T, Huang H-C, Ting I-W, Yeh H-C, Kuo C-C (2018) Uric acid predicts adverse outcomes in chronic kidney disease. A novel insight from trajectory analysis. Nephrol Dial Transplant 33:231\u2013241","journal-title":"Nephrol Dial Transplant"},{"key":"5045_CR10","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53:796\u2013803","journal-title":"Am J Kidney Dis"},{"key":"5045_CR11","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.ajkd.2017.08.017","volume":"71","author":"A Srivastava","year":"2018","unstructured":"Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS (2018) Uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis 71:362\u2013370","journal-title":"Am J Kidney Dis"},{"key":"5045_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jpeds.2012.06.008","volume":"162","author":"DG Noone","year":"2013","unstructured":"Noone DG, Marks SD (2013) Hyperuricemia is associated with hypertension, obesity, and albuminuria in children with chronic kidney disease. J Pediatr 162:128\u2013132","journal-title":"J Pediatr"},{"key":"5045_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00467-013-2549-x","volume":"29","author":"SA Fathallah-Shaykh","year":"2014","unstructured":"Fathallah-Shaykh SA, Cramer MT (2014) Uric acid and the kidney. Pediatr Nephrol 29:999\u20131008","journal-title":"Pediatr Nephrol"},{"key":"5045_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1053\/j.ajkd.2015.06.015","volume":"66","author":"KE Rodenbach","year":"2015","unstructured":"Rodenbach KE, Schneider MF, Furth SL, Moxey-Mims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ (2015) Hyperuricemia and progression of CKD in children and adolescents: the Chronic Kidney Disease in Children (CKiD) cohort study. Am J Kidney Dis 66:984\u2013992","journal-title":"Am J Kidney Dis"},{"key":"5045_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000045939","volume":"87","author":"I Ohno","year":"2001","unstructured":"Ohno I, Hosoya T, Gomi H, Ichida K, Okabe H, Hikita M (2001) Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 87:333\u2013339","journal-title":"Nephron"},{"key":"5045_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000331453","volume":"35","author":"Y Shi","year":"2012","unstructured":"Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H, Yang Q, Johnson RJ, Yu X (2012) Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomised controlled trial. Kidney Blood Press Res 35:153\u2013160","journal-title":"Kidney Blood Press Res"},{"key":"5045_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5414\/CN107813","volume":"80","author":"GY Cheng","year":"2013","unstructured":"Cheng GY, Liu DW, Zhang N, Tang L, Zhao ZZ, Liy ZS (2013) Clinical and prognostic implications of serum uric acid levels on IgA nephropathy: a cohort study of 348 cases with a mean 5-year follow-up. Clin Nephrol 80:40\u201346","journal-title":"Clin Nephrol"},{"key":"5045_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000489962","volume":"48","author":"B Zhu","year":"2018","unstructured":"Zhu B, Yu D, Lv J, Lin Y, Li Q, Yin J, Du Y, Tang X, Mao L, Li Q, Sun Y, Liu L, Li X, Fei D, Wei X, Zhu C, Cheng X, Chen H, Wang Y (2018) Uric acid as a predictor of immunoglobulin A nephropathy progression: a cohort study of 1965 cases. Am J Nephrol 48:127\u2013136","journal-title":"Am J Nephrol"},{"key":"5045_CR19","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","volume":"349","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","unstructured":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857\u20131863","journal-title":"Lancet"},{"key":"5045_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"BM Brenner","year":"2001","unstructured":"Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861\u2013869","journal-title":"N Engl J Med"},{"key":"5045_CR21","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2006121372","volume":"18","author":"FF Hou","year":"2007","unstructured":"Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP (2007) Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18:1889\u20131898","journal-title":"J Am Soc Nephrol"},{"key":"5045_CR22","doi-asserted-by":"crossref","unstructured":"Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, De Jong P, De Zeeuw D, Remuzzi G, Kamper A-L, Levey AS (2007) Progression risk, urinary protein excretion and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18:1959\u20131965","DOI":"10.1681\/ASN.2006101081"},{"key":"5045_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1681\/ASN.2011040430","volume":"23","author":"S Vegter","year":"2012","unstructured":"Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggeneti P (2012) Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 23:165\u2013173","journal-title":"J Am Soc Nephrol"},{"key":"5045_CR24","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/ndt\/gfv429","volume":"31","author":"TF Kropelin","year":"2016","unstructured":"Kropelin TF, De Zeeuw D, Holtkamp FA, Packham DK, Heerspink HJL (2016) Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome. Nephrol Dial Transplant 31:1471\u20131477","journal-title":"Nephrol Dial Transplant"},{"key":"5045_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0022-3476(03)00279-8","volume":"143","author":"D Ellis","year":"2003","unstructured":"Ellis D, Vats A, Moritz ML, Reitz S, Grosso MJ, Janosky JE (2003) Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria. J Pediatr 143:89\u201397","journal-title":"J Pediatr"},{"key":"5045_CR26","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1523-1755.2004.00802.x","volume":"66","author":"E Wuhl","year":"2004","unstructured":"Wuhl E, Mehls O, Schaefer F (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768\u2013776","journal-title":"Kidney Int"},{"key":"5045_CR27","doi-asserted-by":"crossref","unstructured":"Webb NJA, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, Santoro E, Manas D, Gleim GW (2010) Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol 5:417\u2013424","DOI":"10.2215\/CJN.06620909"},{"key":"5045_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/ki.2012.210","volume":"82","author":"NJA Webb","year":"2012","unstructured":"Webb NJA, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C (2012) Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int 82:819\u2013826","journal-title":"Kidney Int"},{"key":"5045_CR29","doi-asserted-by":"crossref","unstructured":"Van den Belt SM, Heerspink HJL, Gracchi V, De Zeeuw D, Wuhl E, Schaefer F; ESCAPE Trial Group (2018) Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD. J Am Soc Nephrol 29:2225\u20132233","DOI":"10.1681\/ASN.2018010036"},{"key":"5045_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47:51\u201359","journal-title":"Am J Kidney Dis"},{"key":"5045_CR31","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Giocoecha","year":"2010","unstructured":"Giocoecha M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5:1388\u20131393","journal-title":"Clin J Am Soc Nephrol"},{"key":"5045_CR32","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","volume":"66","author":"D Sircar","year":"2015","unstructured":"Sircar D, Chatterjee S, Waikhom R, Golay V, Raychaudhury A, Chatterjee S, Pandey R (2015) Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945\u2013950","journal-title":"Am J Kidney Dis"},{"key":"5045_CR33","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/0886022X.2018.1456463","volume":"40","author":"X Liu","year":"2018","unstructured":"Liu X, Zhai T, Ma R, Luo C, Wang H, Liu L (2018) Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 40:289\u2013297","journal-title":"Ren Fail"},{"key":"5045_CR34","doi-asserted-by":"crossref","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kawubara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricamia: a randomized trial. Am J Kidney Dis 72:798\u2013810","DOI":"10.1053\/j.ajkd.2018.06.028"},{"key":"5045_CR35","doi-asserted-by":"crossref","unstructured":"Tiku A, Badve SV, Johnson DW (2018) Urate-lowering therapy for preventing kidney disease progression: are we there yet? Am J Kidney Dis 72:776\u2013778","DOI":"10.1053\/j.ajkd.2018.07.022"},{"key":"5045_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-018-2051-2","volume":"51","author":"J-W Lee","year":"2019","unstructured":"Lee J-W, Lee K-H (2019) Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease. Int Urol Nephrol 51:467\u2013473","journal-title":"Int Urol Nephrol"},{"key":"5045_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10157-018-1652-5","volume":"23","author":"X Liu","year":"2019","unstructured":"Liu X, Wang H, Ma R, Shao L, Zhang W, Jiang W, Luo C, Zhai T, Xu Y (2019) The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5. Clin Exp Nephrol 23:362\u2013370","journal-title":"Clin Exp Nephrol"},{"key":"5045_CR38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5414\/CP203466","volume":"58","author":"AY Yang","year":"2020","unstructured":"Yang AY (2020) Comparison of long-term efficacy and renal safety of febuxostat and allopurinol in patients with chronic kidney diseases. Int J Clin Pharmacol Ther 58:21\u201328","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5045_CR39","doi-asserted-by":"crossref","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N et al; CKD-FIX Study Investigators (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382:2504\u20132513","DOI":"10.1056\/NEJMoa1915833"},{"key":"5045_CR40","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00467-018-3943-1","volume":"33","author":"FG Sharbaf","year":"2018","unstructured":"Sharbaf FG, Assadi F (2018) Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease. Pediatr Nephrol 33:1405\u20131409","journal-title":"Pediatr Nephrol"},{"key":"5045_CR41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2169\/internalmedicine.41.793","volume":"41","author":"T Hamada","year":"2002","unstructured":"Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H, Furuse M, Sonoyama K, Yamamoto Y, Ohtahara A, Igawa O, Shigemasa C, Yamamoto T (2002) Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Int Med 41:793\u2013797","journal-title":"Int Med"},{"key":"5045_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","volume":"20","author":"A Dang","year":"2006","unstructured":"Dang A, Zhang Y, Liu G, Chen G, Song W, Wang B (2006) Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population. J Hum Hypertens 20:45\u201350","journal-title":"J Hum Hypertens"},{"key":"5045_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/jpet.106.112755","volume":"320","author":"T Iwanaga","year":"2007","unstructured":"Iwanaga T, Sato M, Maeda T, Ogihara T, Tamia I (2007) Concentration dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther 320:211\u2013217","journal-title":"J Pharmacol Exp Ther"},{"key":"5045_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","volume":"58","author":"Y Miao","year":"2011","unstructured":"Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58:2\u20137","journal-title":"Hypertension"},{"key":"5045_CR45","doi-asserted-by":"crossref","unstructured":"Shahinfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, Parks JH, Coe FL (1999) Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney Int 56:1879\u20131885","DOI":"10.1046\/j.1523-1755.1999.00739.x"},{"key":"5045_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.amjhyper.2005.08.005","volume":"19","author":"BL Rayner","year":"2006","unstructured":"Rayner BL, Trinder YA, Baines D, Isaacs S, Opie LH (2006) Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics. Am J Hypertens 19:208\u2013213","journal-title":"Am J Hypertens"},{"key":"5045_CR47","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/hr.2012.59","volume":"35","author":"S Ito","year":"2012","unstructured":"Ito S, Naritomi H, Ogihara T, Shimada K, Shimamoto K, Tanaka H, Yoshiike N (2012) Impact of serum uric acid on renal function and cardiovascular events in hypertensive patients treated with losartan. Hypertension Res 35:867\u2013873","journal-title":"Hypertension Res"},{"key":"5045_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3109\/10641963.2014.933968","volume":"37","author":"K Matsumura","year":"2015","unstructured":"Matsumura K, Arima H, Tominaga M, Ohtsuba T, Sasaguri T, Fujii K, Fukuhara M, Uezono K, Morinaga Y, Ohta Y, Otonari T, Kawasaki J, Kato I, Tsuchihashi T; Comfort Investigators (2015) Effect of losartan on serum uric acid in hypertension treated with a diuretic: the COMFORT Study. Clin Exp Hypertens 37:195\u2013196","journal-title":"Clin Exp Hypertens"},{"key":"5045_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1753944716678538","volume":"11","author":"AF Rubio-Guerra","year":"2017","unstructured":"Rubio-Guerra AF, Garro-Almendaro AK, Elizalde-Barrera CI, Suarez-Cuenca JA, Duran-Salgado MB (2017) Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. Ther Adv Cardiovasc Dis 11:57\u201362","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"5045_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.ajkd.2006.04.085","volume":"48","author":"M Zappitelli","year":"2006","unstructured":"Zappitelli M, Parvex P, Joseph L, Paradis G, Grey V, Lau S, Bell L (2006) Derivation and validation of cystatin c-based prediction equations for GFR in children. Am J Kidney Dis 48:221\u2013230","journal-title":"Am J Kidney Dis"},{"key":"5045_CR51","first-page":"1134","volume":"295","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Soto V, Tapia E (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol 295:1134\u20131141","journal-title":"Am J Physiol"},{"key":"5045_CR52","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","volume":"28","author":"M Yu","year":"2010","unstructured":"Yu M, Sanchez-Lozada LG, Johnson RJ (2010) Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric-acid induced endothelial dysfunction. J Hypertension 28:1234\u20131242","journal-title":"J Hypertension"},{"key":"5045_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.2217\/pgs.15.52","volume":"16","author":"H Sun","year":"2015","unstructured":"Sun H, Qu Q, Qu J, Lou X-Y, Peng Y, Zeng Y, Wang G (2015) URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. Pharmacogenomics 16:855\u2013863","journal-title":"Pharmacogenomics"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-021-05045-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-021-05045-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T14:11:04Z","timestamp":1631801464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-021-05045-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1007\/s00467-021-05045-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"assertion":[{"value":"6 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, did not provide any sponsorship for the project and had no role in the analysis of the data or the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}